Table 2.
Immunosuppression in Transplant Cohort
| Patient | Donor Type | Time from Transplant to SARS-CoV-2 (mo) | Induction Immunosuppression | Maintenance Immunosuppression |
||||
|---|---|---|---|---|---|---|---|---|
| CNI | mTORi | Antimetabolite | Pred | CNI Level at Time of Presentation | ||||
| 1 | DCD | 122 | ATG, MP | Siro | MMF | Yes | ||
| 2 | DCD | 10 | ATG, MP | Tac | MMF | Yes | 11 | |
| 3 | DBD | 135 | Basiliximab, MP | Tac | Aza | 7 | ||
| 4 | LD | 218 | Basiliximab, MP | Tac | Aza | 18 | ||
| 5 | LD | 122 | Basiliximab, MP | Tac | MMF | Yes | 4.5 | |
| 6 | LD | 64 | Basiliximab, MP | Tac | MMF | 12.5 | ||
| 7 | DBD | 356 | MP | Cicl | 61 | |||
| 8 | DBD | 243 | Basiliximab, MP | Tac | Yes | 15 | ||
| 9 | DBD | 204 | Basiliximab, MP | Tac | Aza | Yes | 18.7 | |
| 10 | DBD | 317 | MP | Tac | Aza | Yes | 18 | |
| 11 | DCD | 9 | ATG, MP | Tac | MMF | 8.4 | ||
| 12 | LD | 86 | Basiliximab, MP | Tac | MMF | Yes | 7.3 | |
| 13 | DCD | 153 | ATG, MP | Tac | Aza | Yes | 9 | |
Abbreviations: ATG, antithymocyte globulin; Aza, azathioprine; Cicl, ciclosporin; CNI, calcineurin inhibitor; DBD, deceased after brainstem death; DCD, deceased after circulatory death; LD, living donor; MMF, mycophenolate mofetil; MP, methylprednisolone; mTORi, mammalian target of rapamycin inhibitor; Pred, prednisolone; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Siro, sirolimus; Tac, tacrolimus.